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Abstract: 
 
Aim: To analyze demographic, clinical and paraclinical data of a cohort with first episode of acute 
myelitis in a Portuguese hospital, as any description in the Portuguese population was found in literature. 
Describe the differences between myelitis associated and not associated with multiple sclerosis (MS). 
Methods: 5 year- retrospective study based on medical records of admitted patients with a spinal cord 
syndrome. Patients with age above 18 and inflammatory etiologies were included. 
Results: 74 myeolopathies were identified but only 30 myelitis were included. In myelitis group, the final 
diagnosis were: clinically isolated syndrome, MS, systemic lupus erythematosus, post-infectious myelitis 
and idiopathic form. Differences statistically significant between the groups were found in these subsets: 
presence of autonomic symptoms and gait autonomy at the onset, brain magnetic resonance imaging 
(MRI) results and longitudinal extension in spinal cord MRI. The recurrence of myelitis was also 
different among groups. The diagnostics groups were further classified in acute myelitis associated with 
MS and other acute myelitis. The statistically significant differences found among these groups were the 
same as in the groups described above. The neurological disability at the end of the follow-up was 
correlated with motor symptoms, hyperreflexia and visual evoked potencials with increased latencies and 
inversely correlated with an autonomous gait at the onset.  
Conclusion: The principal aim of describing an acute myelitis cohort in Portuguese population was 
accomplished. In order to make a better characterization enabling more accurate application of diagnostic 
criteria and treatment options, multicentre studies should be performed. 
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1. Introduction 
Acute transverse myelopathy is a clinical definition of an acute neurological condition that reflects 
impairment of spinal cord function. [33] It results in loss of motor, sensory and autonomic functions 
below the level of the lesion [27], indicating the need of urgent therapy. [5] The lesion typically spans 
multiple vertebral segments and is not radiologically or pathologically transverse; the term transverse has 
been retained over decades because of the importance of a spinal sensory level in making the 
diagnosis.[29]  
Although anatomically speaking spinal cord syndromes are well-defined, they have an extensive list of 
differential diagnosis.  
First of all, it is important to rule out, by Magnetic Resonance Imaging (MRI), a compressive etiology by 
disc herniation, a tumor metastasis or spondylolisthesis, because a structural cause needs immediate 
neurosurgical evaluation. 
Beyond the compressive etiology, myelopathies can occur due to inflammatory and non-inflammatory 
causes. The latter includes vascular, radiation, metabolic, neoplastic and paraneoplastic etiologies. [1, 13] 
The former can include systemic autoimmune disorders (Systemic Lupus Erythematosus [17], Sjögren 
syndrome [3, 12], antiphospholipid antibody syndrome [20], mixed connective tissue disease [22], 
systemic sclerosis [35], ankylosing spondilitis [23], and sarcoidosis [18]), infections [1, 13, 27] and 
primary central nervous system demyelinating disorders [1]. 
Even among the last group there are several differential diagnosis, such as Multiple Sclerosis (MS), 
Neuromyelitis optica (NMO), Acute Disseminated Encephalomyelitis and the idiopathic form [9], which 
can be the ultimate diagnosis despite the extensive work-up. 
A lumbar puncture should be performed to distinguish between inflammatory and non inflammatory 
myelopathy. If the cerebral spinal fluid (CSF) shows moderate pleocytosis or increased immunoglobulin 
G (IgG) index and gadolinium enhancement is seen in spinal cord MRI, an inflammatory cause should be 
suspected and the extent of demyelination should be measured. [1] 
The management of these patients is made in emergency care units with high-dose intravenous steroid 
therapy [16] or plasmapheresis, in case of severe demyelination [15]. 
Independent of etiology, the prognosis of these patients is highly variable and unpredictable. A division 
can be made in three groups: one third completely recovers, one third presents residual symptoms and the 
remaining have no improvement at all [25]. 
We didn’t find any description of this syndrome in the Portuguese population in literature, so the aim of 
our study is describing a group of patients admitted with the first episode of an non infectious 
inflammatory myelopathy, ie non infectious myelitis, in a Portuguese hospital and analyze the 
demographic, clinical and paraclinical data, in order to characterize them and correlate the findings with 
their outcome. 
 
2. Patients and methods 
A retrospective, descriptive and analytical study will be carried based on medical records of admitted 
patients with a spinal cord syndrome, between 01/01/2007 and 31/12/2011, in Neurology department of 
Centro Hospitalar de São João, E.P.E., Porto, Portugal.  
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Potential study subjects were identified by querying the inpatient database for different groups of 
discharge diagnosis: Encephalitis, myelitis and encephalomyelitis; spino-cerebellar diseases; diseases of 
the spinal cord not categorized in other group (NCOG); multiple sclerosis; demyelinating diseases 
NCOG; paralytic syndromes NCOG. 
 
2.1 Definition of cases 
The enrolled patients had sensory (paresthesias, dysesthesias, hypoaesthesias, sensory level), motor 
(paraparesis, tetraparesis, monoparesis, hemiparesis) and/or autonomic (increased urinary urgency, bowel 
or bladder incontinence, difficulty or inability to void, incomplete evacuation or bowel constipation)[28] 
initial symptoms compatible with a spinal cord syndrome with progression from onset to nadir of 4 hours 
to 21 days[1]. Patients whose symptoms reach maximal severity in less than four hours from onset are 
presumed to have an ischemic etiology [1], therefore out of the scope of this study.  
Patients matching the clinical criteria of spinal cord syndrome, as previously described, with age above 18 
were included in the study. 
The compressive, vascular, neoplastic, paraneoplastic, metabolic, infectious and radiation etiologies were 
excluded from the final evaluation and characterization of the cases of myelitis. 
The initial diagnosis of acute transverse myelitis after the follow-up were categorized in subgroups 
according to the different etiologies. 
 
2.2. Data collection 
2.2.1. Clinical data 
The following data was collected from Medical Charts: gender, age, date of admission and discharge, 
motive of admission, neurological exam aspects, previous diseases relevant to the case, family history of 
neurological disease, final diagnosis, therapeutics and evolution of the patient. 
The dysfunction was staged with Expanded Disability Status Scale (EDSS) [19] and this classification 
was revised by a neurologist specialized in demyelinating diseases and certified by Neurostatus e-Test. In 
order to compare the last visit EDSS in patients with different time follow-ups, this score was converted 
to Multiple Sclerosis Severity Score (MSSS).[26] 
 
2.2.2 Supplementary exams 
Infectious diseases screening tests were performed in most cases. Serology for antibodies in serum to 
Herpes Simplex Virus (HSV) 1 and 2, Varicela Zoster Virus (VZV), Human T-cell Lymphotropic Virus-1, 
Borrelia spp, Human Immunodeficiency Virus (HIV), hepatitis B and C and Mycoplasma were 
accomplished. Serologies and/or Polimerase Chain Reaction (PCR) in CSF were also carried out to 
Borrelia spp, Treponema pallidum, Mycobacterium Tuberculosis, M. pneumoniae, HSV-1, HSV-2, 
Human Herpes virus-6, Enterovirus, HIV, Epstein-Barr Virus, Cytomegalovirus, VZV and Toxoplasma 
gondii.   
Auto-immune diseases were screened by anti-nuclear antibodies, anti double stranded DNA  antibodies, 
anticardiolipin antibodies, anti-extractable nuclear antigens antibodies and circulating imunocomplexes 
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assays. Angiotensin converting enzyme was also titrated in CSF and vitamins B12 and E and copper 
levels were dosed in serum. Thyroid function tests, as well as anti-thyroid antibodies, were also requested.  
Brain MRI was classified in three groups according to the Barkoff/ Tintore criteria [4, 34] : normal, 
suggestive of MS (≥3 present criteria) or non suggestive of MS (< 3 criteria).  
Spinal cord MRI was analyzed by number of lesions, their longitudinal and transversal localization and 
extension, signal in T2-weighed scans, enhancement by gadolinium contrast and swelling of the cord. The 
first scan was carried during the acute phase. 
Visual evoked potentials (VEP) were evaluated in most of the patients and subdivided in normal and 
increased latencies. 
Inflammatory signs in CSF were assessed by number of cells (pleocytosis ≥10 total cells/mm3)[31], IgG 
index (≥0,6) and the presence of oligoclonal IgG bands (OCB).  
Serum  NMO-IgG antibodies were tested when there was a suspicion of a NMO spectrum disorder by 
ELISA, using a commercial sampling kit (INNOTEST AQP4Ab ELISA). 
 
2.3. Statistical analysis 
The data was saved and analyzed using IBM SPSS Statistics 20 software program; missing values were 
excluded from the analysis. Categorical variables were expressed as percentages. Continuous variables 
were presented as means with standard deviation or as medians with range. The different diagnostic 
groups were compared using Mann-Whitney U, Krushkal-Wallis, chi-square and Fisher’s exact tests. p 
values <0,05 were considered statistically significant. 
 
2.4. Ethical aspects 
The study started after approval by Ethics Committee for Health of  Centro Hospitalar de São João, 
E.P.E.. 
 
3. Results 
After querying the inpatient database, 451 patients were found. However, after excluding patients under 
18 years old, absence of a true spinal cord syndrome and presentations explained by a disease diagnosed 
before 2007, only 74 cases of myelopathies remained. Of this 74, only 30 myelitis were included in the 
study, following the exclusion of compressive spondylotic (n=18), associated with radiotherapy (n=1), 
vascular (n=8), subacute combined degeneration (n=8), paraneoplastic (n=3) and infectious (n=6) 
etiologies. Among the last ones, four cases of Neuroborreliosis, one HSV-1 and one HTLV-1 CNS 
infections were identified (Figure 1). In Myelitis patients group, five patients (16,7%) had the diagnosis 
of clinically isolated syndrome (CIS), fourteen (46,7%) of multiple sclerosis (MS), one (3,3%) of 
systemic lupus erythematosus, four (13,3%) of post-infectious myelitis and six (20%) with the idiopathic 
form. One patient in the MS group was diagnosed with primary progressive subtype.  
 
3.1. Clinical Findings 
Of the 30 myelitis patients, 16 (53,3%) were female and 14  (46,7%) were male and all of them were 
Caucasian. Onset of the disease occurred within a median of 7 days (ranging from 1 to 21) at the mean 
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age of 36,7 ±11,15 years. The most frequent symptoms were sensory disturbances (96,7%): hiposthesias 
in 21 (70%), disesthesias in 10 (33,3%), paresthesias in 14 (46,7%) and sensory level in 18 (60%). Motor 
symptoms were present in 18 cases (60%): hemiparesis- 3(10%); monoparesis- 3 (10%); paraparesis- 8 
(26,7%) and tetraparesis- 4 (13,3%). Bilaterality of symptoms was found in 18 (60%).  Hyperreflexia was 
present in 13 (43,3%) patients and 7 (23,3%) were unable to walk. Six patients (43,3%) referred pain and 
only 3 (10%) had a positive L’Hermitte sign. The median of the follow-up time (between first episode 
and last ambulatory visit) was 10 months (range:2-58).  
Eight patients (26,7%) had recurrence of the myelitis, seven from the MS group and one from the IATM 
group, within a median time of 4,5 months (range: 1-11). Two  other patients from the MS group had non 
spinal relapses, one 17 months after and other 5 months after; both had motor symptoms compatible with 
encephalic lesions.  
From the 6 patients who remained diagnosed as idiopathic, two completely fulfilled the diagnostic criteria 
from Transverse Acute Myelitis Consortium Working Group[1]. Two didn’t have bilateral symptoms but 
had instead an hemi-level, hence matching the criteria for acute partial transverse myelitis proposed by 
Scott et al.[32] The other two did have bilateral symptoms, however have not shown a clearly defined 
sensory level.    
Only 9 patients (30%) had complete recovery, nevertheless the median EDSS at discharge was 1.5 (0-7.0) 
and the mean MSSS at the last follow-up visit was 2,77 (0,35-9,59).  
All but 3 patients were treated with methylprednisolone (1g/d for 5 days), in cases of poor steroid 
response this treatment was followed by IV immunoglobulins (3 cases), plasmapheresis (2 cases), 
azathioprine (one) and cyclophosphamide (one).   
 
3.2 Supplementary tests 
All patients were submitted to at least one MRI scan of the spinal cord during the acute phase of the 
disease and, with one exception, an abnormal scan was found in all patients. 65,5% had a single lesion 
and 34,5% had multiple lesions (all lengthening ≤ 2 cord segments). 20,7% had a longitudinally extensive 
myelitis (≥3 cord segments) and 79,3% had a lesion spanning  ≤ 2 vertebral segments. Eleven patients 
(36,7%) had lesion/lesions located in the cervical spinal cord, eight (26,7%) with thoracic location, seven 
(23,3%) with both cervical and thoracic, two (6,6%) with sacral and one patient with a lesion extending 
by the all length of the cord. In transversal section, 23,3% had centromedullary lesions, 46,7% peripheral 
lesions, 13,3% holocord lesions, 6,7% had a mixed type. Eleven ( 37,9%) patients presented with cord 
swelling and twenty-one (72,4%) with gadolinium enhancement.  
A Brain MRI was also taken in all the patients with 6 (20%) of them having a normal scan, 6 (20%) 
having an abnormal scan but with less than 3 Barkoff/ Tintore criteria [4, 34] and 18 (60%) with 3 or 
more criteria present. 
In CSF analysis, 11/30 (36,7%) showed pleocytosis, 19/25 (76%) an elevated IgG index and 16/28 
(57,1%) positive OCB. 
VEPs showed increased latencies in 5/23 (21,7%) patients. Of the 7 NMO-IgG antibodies requested, 6 
were negative and one isn’t available yet. 
 
7 
 
3.3 Comparisons between groups 
Table 1 shows the data for this study sample. There were no statistically significant differences between 
the diagnostic groups with respect to gender, age at the onset, symptoms (except autonomic symptoms 
(p=0,04) and gait autonomy (p=0,028)), CSF analysis including IgG index and OCB, VEP results and 
disability measured by EDSS at the onset, at discharge and at the end of follow-up by MSSS. Differences 
statistically significant between the groups were found in brain MRI (p=0,000) results and in the 
longitudinal extension (p=0,03) in spinal cord MRI. The recurrence of myelitis was also different among 
groups (p=0,008). 
In order to understand the differences the diagnostics groups were further classified in acute myelitis 
associated with MS (AM-MS) and  other acute myelitis (AM-O), either associated with other diseases or 
the idiopathic form. The patients with CIS were included in AM-MS group, because they were isolated in 
time, but all of them had dissemination in space according to the 2010 revisions to the McDonald 
criteria.[24] The statistically significant differences found among AM-MS and AM-O groups were the 
same found in the groups described above (Table 2). Inability to deambulate is negatively associated with 
MS (OR=0,046), so was the presence of autonomic symptoms (OR=22,67). The differences in MRI, brain 
and spinal cord, were the same, as well. 
The recurrence of symptomatic episodes was associated with AM-MS group (table 2) and with EDSS>2.5 
at the onset ( p=0,018; OR=9,6 (1,48-62,16) ). 
Longitudinally extensive cord lesions were strongly associated with presence of motor (p=0,028) and 
autonomic (p=0,000) manifestations and symmetrical symptoms (p=0,028), loss of fully ambulatory 
capacity (p=0,001) and absence of brain MRI suggestive of MS (p=0,000). (table 3) 
At discharge from the hospital, EDSS>2.5 was only associated to positive OCB in CSF (p=0,028). (Table 
4) The neurological disability at the end of the follow-up measured by MSSS superior to 2.5 was 
correlated with motor symptoms (p=0,002), hyperreflexia (OR=12)and VEP with increased latencies 
(OR=20) and inversely correlated with an autonomous gait at the onset (OR=0,111). (Table 5) 
 
4. Discussion 
This study describes the clinical course of 30 patients with first episode of acute myelitis. Diagnosis of 
MS was the most prevalent and its percentage superior to the ones found in recent studies[2, 6, 7, 21], 
despite similar presentations in others [8, 10]. This finding probably dues to the inclusion of patients with 
partial myelitis, without bilateral symptoms or a clearly defined sensory level as advocated by Transverse 
Myelitis Consortium Working Group.[1] These weren’t applied as inclusion criteria, because we didn’t 
want to exclude any kind of inflammatory myelopathy, except for th infectious etiologies, once this is the 
first Portuguese population description of this syndrome. We didn’t find any NMO case, which is very 
uncommon [2, 6, 7, 21]; presumably this pathology is even less ordinary in our population, since, as far as 
we  are concerned, there is only one described case in literature in the Portuguese adult population.[11]   
Demographic differences were not found between groups. Although they have been described [8, 30], 
they are currently not useful in distinguishing causes of myelitis, according to an evidence based 
guideline recently released.[31] 
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The differences found among groups (five initial diagnostic groups and AM-MS/AM-O), correlating MS 
positively with an abnormal brain MRI with ≥3 Barkhof criteria, multiple and longitudinal small lesions 
in spinal MRI and recurrence of symptomatic myelitis, and negatively with loss of gait autonomy and 
autonomic symptoms, were as the expected.[32] The longitudinal extension of the spinal lesions was 
associated with the severity of manifestations and inversely associated with brain MRI suggestive of MS, 
although there was no correlation with long term disability as it was shown by other groups.[6, 21] 
However, this may be due to the reduced number of patients with longitudinal extensive myelitis. 
Superior neurological impairment, at hospital discharge, was associated with negative OCB and, at the 
end of the follow-up, with presence of motor symptoms, as was found by Gajofatto at al.[10] 
Hyperreflexia, inability to walk autonomously at the onset and VEP with increased latencies were also 
associated with MSSS superior to 2.5 at the end of the follow-up. Despite the findings of statistically 
significance, we don’t know if they are reproducible owing to the small sample size. 
This study has several limitations. The reduced number of cases is the strongest limitation in our point of 
view, however as acute transverse myelitis is a rare presentation it is very difficult to have large cohorts in 
a single hospital. The fact that it is retrospective hampers the uniformity in supplementary testing. For 
example we didn’t report the results of somatosensory evoked potentials which once normal can predict 
better prognosis.[14]  Nonetheless our principal aim was accomplished since we characterize 
demographically, clinically and paraclinically a Portuguese myelitis cohort. In order to understand if our 
findings are reproducible and indeed correlate with the outcome of patients, other studies should be 
performed. We appeal to multicentre studies, so that better characterization of our population is achieved 
and the application of diagnostic criteria and treatment options are more accurate and standardized. 
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Table 1  Characteristics of the study subjects 
Characteristics MS CIS PI SLE IATM 
p 
value* 
Gender (F:M) 8:6 3:2 0:4 1:0 4:2 0,196 
Age at onset 
33,07 
(10,042) 
36,60 
(13,903) 
48,50 
(13,178) 
36 a 
37,50 
(7,176) 
0,277** 
Motor symptoms 
Tetraparesis 
Paraparesis 
Hemiparesis 
Monoparesis 
9/14 
3 
2 
3 
1 
2/5 
0 
1 
0 
1 
3/4 
1 
2 
0 
0 
1/1 
0 
1 
0 
0 
3/6 
0 
2 
0 
1 
0,693 
 
 
0,697 
 
 
Hyperreflexia 
8/14 2/5 1/4 1/1 1/6 0,319 
 
Sensory symptoms 
13/14 5/5 4/4 1/1 6/6 0,881 
Paresthesias 7/14 2/5 1/4 1/1 3/6 0,722 
Dysesthesias 5/14 2/5 1/4 0/1 3/6 0,944 
Hyposthesias 11/14 3/5 4/4 1/1 3/6 0,205 
Sensory level 
 
8/14 3/5 2/4 1/1 4/6 0,911 
Bilateral symptoms 8/14 1/5 4/4 1/1 4/6 0,145 
 
Autonomous gait 
13/14 5/5 2/4 0/1 3/6 0,028 
 
Autonomic symptoms 
2/14 0/5 4/4 1/1 3/6 0,04 
 
Pain 
2/12 0/5 2/4 0/1 2/6 0,319 
 
EDSS at onset 
3.0 (1.0-7.0) 1.5 (1.0-3.0) 3.0 (1.0-7.0) 2.5 a 4.0(1.0-8.0) 0,368** 
 
Spinal cord MRI 
      
Single lesion 6/13 2/5 4/4 1/1 6/6 
0,052 
Multiple lesions 7/13 3/5 0/4 0/1 0/6 
Longitudinal extension       
≤ 2 cord segments 13/13 5/5 1/4 0/1 4/6 
0,03 
≥ 3 cord segments 0/13 0/5 3/4 1/1 2/6 
Gadolinium 
Enhancement 
10/13 4/5 2/4 0/1 5/6 0,371 
Cord swelling 4/13 3/5 2/4 0/1 2/6 0,694 
 
Brain MRI 
      
Normal 0/14 0/5 1/4 0/1 5/6 
0,000 Suggestive of MS 13/14 5/5 0/4 0/1 0/6 
Non suggestive of MS 1/14 0/5 3/4 1/1 1/6 
 
CSF analysis 
      
Pleocytosis 5/14 2/5 3/4 0/1 1/6 0,383 
OCB + 10/14 3/5 1/3 - 2/6 0,352 
IgG index >0,6 9/11 4/5 2/3 - 4/6 0,878 
 
VEPs 
      
Normal 10/13 3/4 0/1 1/1 4/4 
0,284 
Increased latencies 3/13 1/4 1/1 0/1 0/4 
 
EDSS at discharge 
1.5 (0-3.5) 1.0 (0-1.5) 2.0 (0-2.5) 0a 1.5 (0-7.0) 0,375** 
 
Full Recovery 
 
2/14 2/5 1/3 1/1 3/6 0,262 
Recurrence of myelitis 
 
9/13 0 0/3 0/1 1/6 0,008 
MSSS 
2,9662 
(2,04159) 
1,5820 
(1,0063) 
2,99933 
(2,64379) 
- a 
2,9667 
(3,50724) 
0,625** 
Abbreviations: MS: multiple sclerosis; CIS: clinically isolated syndrome; PI: post-infectious; SLE:nSystemic Lupus Eritematous; IATM: idiopathic 
acute transverse myelitis; Gender (F:M)- Female:Male; OCB +: positive oligoclonal bands in cerebrospinal fuid. 
*Calculated using chi-square test 
**Calculated using Krushkall-Wallis test 
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Table 2 – Variables associated with MS group 
 AM-MS AM-O OR (95% CI)*  p value** 
Autonomous gait     
Absent 1 6 
0,046 
(0,004-0,479) 
0,04 Present 
 
18 5 
Autonomic symptoms     
Absent 17 3 
22,67 
(3,14-1633,63) 
0,001 Present 
 
2 8 
Brain MRI     
Normal 0 6 
 0,000 
Non suggestive of MS 1 5 
Suggestive of MS 
 
18 0 
Spinal cord MRI     
Single lesion 8 11 
 0,003 
Multiple lesions 10 0 
Longitudinal extension     
≤ 2 cord segments 18 5  0,001*** 
≥ 3 cord segments 0 6   
Recurrence of myelitis 
Absent 
Present 
 
8 
9 
 
9 
1 
0,0099 
(0,010-0,961) 
0,042 
Abbreviations: OR: odds ratio; CI: confidence interval 
* Risk of having MS with the presence of certain characteristics was calculated by an OR with 95% CI. These were wide due to the 
small sample size. 
**Calculated by Fisher exact test or ***chi-square test 
 
Table 3- Variables associated with longitudinal extension of cord lesions 
 ≤2 cord segments ≥3 cord segments OR (95% CI)  p value** 
Motor symptoms     
Present 11/23 6/6 
 0,028 Absent 
 
12/23 0/6 
Bilateral symptoms     
Present 11/23 6/6 
 0,028 Unilateral 
 
12/23 0/6 
Autonomous gait     
Present 21/23 1/6 
0,019 
(0,001-0,254) 
0,001 Absent 
 
2/23 5/6 
Autonomic symptoms     
Present 4/23 6/6 
 0,000 Absent 
 
19/23 0/6 
Brain MRI     
Normal 5/23 1/6  
0,000*** 
Non suggestive of MS 1/23 5/6  
Suggestive of MS 
 
17/23 0/6 
 
* Risk of having a longitudinal extensive lesion was calculated by an OR with 95% confidence interval (CI) 
** values calculated using chi-square and Fisher exact test or *** chi-square test 
 
Table 4 - Variables associated with disability at discharge after first episode 
 EDSS ≤ 2.5 EDSS > 2.5 p value* 
OCB    
Positive 15/23 0/4 
0,028 Negative 
 
8/23 4/4 
Abbreviations: OCB- oligoclonal bands in cerebrospinal fluid; *values calculated using Fisher exact test 
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Table 5 - Variables associated with disability at the end of the follow-up 
 MSSS ≤ 2.5 MSSS > 2.5 OR (95% CI)  
of MSSS > 2.5* 
p value** 
Motor symptoms     
Present 8/20 10/10 
 0,002 Absent 
 
12/20 0/10 
Autonomous gait     
Present 18/20 5/10 
0,111 
(0,016-0,755) 
0,026 Absent 
 
2/20 5/10 
Hyperreflexia     
Present 5/20 8/10 
12 
(1,885-76,376) 
0,007 Absent 
 
15/20 2/10 
VEP     
Increased latencies 1/16 4/7 
20 
(1,613-247,981) 
0,017 Normal 
 
15/16 3/7 
Abbreviations: VEP- Visual Evoked Potentials 
* Risk of having a MSSS> 2.5  was calculated by an OR with 95% confidence interval (CI) 
** values calculated using Fisher exact test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
451 cases 
Myelopathies 
n =74 
Myelitis 
n =30 
SCM 
n =18 
Vascular 
n =8 
SCD 
n =8 
Infectious 
n =6 
Paraneoplastic 
n =3 
Radiotherapy 
n =1 
HSV-1 
N =1 
HTLV-1 
n =1 
Neuroborreliosis 
n =4 
Figure 1- Diagram showing etiologies of the acute myelopathies included and excluded from the 
study 
Abbreviations: SCM: Spondilotic Compressive Myelopathy; SCD: Subacute Combined Degeneration; HTLV-1: Human T-
cell Lymphotropic Virus-1; HSV-1: Herpes Simplex Virus-1  
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under consideration for publication anywhere else; that its publication has been approved by all co-
authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institute where the 
work has been carried out. The publisher will not be held legally responsible should there be any claims 
for compensation. 
Permissions 
Authors wishing to include figures, tables, or text passages that have already been published elsewhere 
are required to obtain permission from the copyright owner(s) for both the print and online format and to 
include evidence that such permission has been granted when submitting their papers. Any material 
received without such evidence will be assumed to originate from the authors. 
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